AngioDynamics, Inc.

NasdaqGS:ANGO Stock Report

Market Cap: US$361.2m

AngioDynamics Management

Management criteria checks 2/4

AngioDynamics' CEO is Jim Clemmer, appointed in Apr 2016, has a tenure of 8.67 years. total yearly compensation is $5.01M, comprised of 15.6% salary and 84.4% bonuses, including company stock and options. directly owns 1.17% of the company’s shares, worth $4.24M. The average tenure of the management team and the board of directors is 6.5 years and 8.8 years respectively.

Key information

Jim Clemmer

Chief executive officer

US$5.0m

Total compensation

CEO salary percentage15.6%
CEO tenure8.7yrs
CEO ownership1.2%
Management average tenure6.5yrs
Board average tenure8.8yrs

Recent management updates

Recent updates

There Is A Reason AngioDynamics, Inc.'s (NASDAQ:ANGO) Price Is Undemanding

Dec 10
There Is A Reason AngioDynamics, Inc.'s (NASDAQ:ANGO) Price Is Undemanding

AngioDynamics, Inc. (NASDAQ:ANGO) Just Released Its Annual Results And Analysts Are Updating Their Estimates

Jul 19
AngioDynamics, Inc. (NASDAQ:ANGO) Just Released Its Annual Results And Analysts Are Updating Their Estimates

Improved Revenues Required Before AngioDynamics, Inc. (NASDAQ:ANGO) Stock's 26% Jump Looks Justified

Jul 18
Improved Revenues Required Before AngioDynamics, Inc. (NASDAQ:ANGO) Stock's 26% Jump Looks Justified

AngioDynamics: A Story To Monitor

May 14

A Leaner AngioDynamics Is A High-Risk Execution-Driven Story

Apr 09

AngioDynamics, Inc.'s (NASDAQ:ANGO) Shares Bounce 26% But Its Business Still Trails The Industry

Apr 06
AngioDynamics, Inc.'s (NASDAQ:ANGO) Shares Bounce 26% But Its Business Still Trails The Industry

AngioDynamics: Restructuring Initiative May Not Go Far Enough

Jan 14

AngioDynamics (NASDAQ:ANGO) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Oct 12
AngioDynamics (NASDAQ:ANGO) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

AngioDynamics (NASDAQ:ANGO) Is Carrying A Fair Bit Of Debt

Mar 31
AngioDynamics (NASDAQ:ANGO) Is Carrying A Fair Bit Of Debt

AngioDynamics Non-GAAP EPS of -$0.06 misses by $0.04, revenue of $81.5M misses by $1.93M, reaffirms FY guidance

Oct 06

AngioDynamics: Lack Of Upside Capture Remains, Continue To Hold

Sep 29

Is AngioDynamics (NASDAQ:ANGO) Using Debt In A Risky Way?

Sep 02
Is AngioDynamics (NASDAQ:ANGO) Using Debt In A Risky Way?

AngioDynamics Non-GAAP EPS of $0.01 in-line, revenue of $87M beats by $4.09M

Jul 12

CEO Compensation Analysis

How has Jim Clemmer's remuneration changed compared to AngioDynamics's earnings?
DateTotal CompensationSalaryCompany Earnings
Aug 31 2024n/an/a

-US$243m

May 31 2024US$5mUS$783k

-US$184m

Feb 29 2024n/an/a

-US$192m

Nov 30 2023n/an/a

-US$14m

Aug 31 2023n/an/a

US$6m

May 31 2023US$4mUS$756k

-US$52m

Feb 28 2023n/an/a

-US$37m

Nov 30 2022n/an/a

-US$33m

Aug 31 2022n/an/a

-US$33m

May 31 2022US$6mUS$736k

-US$27m

Feb 28 2022n/an/a

-US$40m

Nov 30 2021n/an/a

-US$38m

Aug 31 2021n/an/a

-US$34m

May 31 2021US$4mUS$720k

-US$32m

Feb 28 2021n/an/a

-US$169m

Nov 30 2020n/an/a

-US$171m

Aug 31 2020n/an/a

-US$170m

May 31 2020US$3mUS$716k

-US$167m

Feb 29 2020n/an/a

-US$7m

Nov 30 2019n/an/a

-US$6m

Aug 31 2019n/an/a

-US$7m

May 31 2019US$3mUS$687k

-US$11m

Feb 28 2019n/an/a

-US$34m

Nov 30 2018n/an/a

-US$16m

Aug 31 2018n/an/a

-US$12m

May 31 2018US$3mUS$643k

-US$6m

Compensation vs Market: Jim's total compensation ($USD5.01M) is above average for companies of similar size in the US market ($USD2.22M).

Compensation vs Earnings: Jim's compensation has increased whilst the company is unprofitable.

CEO

Jim Clemmer (60 yo)

8.7yrs

Tenure

US$5,005,971

Compensation

Mr. James C. Clemmer, also known as Jim, has been the Chief Executive Officer, President and a Director of AngioDynamics, Inc. since joining it on April 04, 2016. Mr. Clemmer served as Group President of t...

Leadership Team

NamePositionTenureCompensationOwnership
James Clemmer
CEO, President & Director8.7yrsUS$5.01m1.17%
$ 4.2m
Stephen Trowbridge
Executive VP & CFO5.2yrsUS$1.82m0.26%
$ 946.0k
Chad Campbell
Senior VP and GM of Global Vascular Access & Oncology Business Unit8.6yrsUS$1.01m0.18%
$ 646.2k
Warren Nighan
Senior Vice President of Regulatory Affairs7.7yrsUS$995.08k0.11%
$ 407.8k
Laura Piccinini
Senior VP & GM of Endovascular Therapies and International3.5yrsUS$1.23m0.14%
$ 497.9k
Saleem Cheeks
Vice President of Communications4.8yrsno datano data
Benjamin Davis
Senior Vice President of Business Development & Strategy9.8yrsno datano data
Marna Bronfen-Moore
Senior Vice President of Human Resources5.3yrsno datano data
Kim Seabury
Senior Vice President of Information Technology13.3yrsno datano data
Juan Serna
Senior Vice President of Scientific & Clinical Affairs3.9yrsno datano data

6.5yrs

Average Tenure

56yo

Average Age

Experienced Management: ANGO's management team is seasoned and experienced (6.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
James Clemmer
CEO, President & Director8.7yrsUS$5.01m1.17%
$ 4.2m
Jan Reed
Independent Director8.1yrsUS$225.11k0.21%
$ 776.6k
Wesley Johnson
Independent Director17.9yrsUS$234.81k0.30%
$ 1.1m
Howard Donnelly
Independent Non-Executive Chairman20.8yrsUS$262.01k0.37%
$ 1.3m
Eileen Auen
Independent Director8.9yrsUS$229.13k0.21%
$ 773.8k
Michael Dake
Member of the Scientific Advisory Boardno datano datano data
Frank Veith
Member of the Scientific Advisory Boardno datano datano data
Thomas Sos
Member of the Scientific Advisory Boardno datano datano data
Stephen Kee
Member of the Scientific Advisory Boardno datano datano data
John Kaufman
Member of the Scientific Advisory Boardno datano datano data
Jacob Cynamon
Member of the Scientific Advisory Boardno datano datano data
Karen Licitra
Independent Director5.4yrsUS$224.51k0.18%
$ 646.8k

8.8yrs

Average Tenure

63.5yo

Average Age

Experienced Board: ANGO's board of directors are considered experienced (8.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 02:27
End of Day Share Price 2024/12/20 00:00
Earnings2024/08/31
Annual Earnings2024/05/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

AngioDynamics, Inc. is covered by 17 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Matthew TaylorBarclays
John YoungCanaccord Genuity
William PlovanicCanaccord Genuity